Name: BIOGEN INC (BIIB) Stock
Brand: BIOGEN INC
Rating: 7 (3 reviews)

BIIB Latest News, Press Relases and Analysis

All

Press Releases

14 hours ago - By: Chartmill - Mentions: APP TROW AZO FTNT ...

What's going on in today's session: S&P500 gap up and gap down stocks

17 days ago - By: Chartmill - Mentions: BMY CNC HUM MOH ...

Which S&P500 stocks are moving before the opening bell on Monday?

2 days ago - By: Biogen Inc.

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

4 days ago - By: The Motley Fool - Mentions: ALNY SNY REGN VIR ...

Is Alnylam Pharmaceuticals a Millionaire Maker?

6 days ago - By: Zacks Investment Research - Mentions: RVMD

Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?

6 days ago - By: The Motley Fool - Mentions: NVO LLY ESAI

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?

6 days ago - By: Zacks Investment Research - Mentions: RPRX DNLI TAK

Denali Enters Into a $275M Funding Deal With Royalty Pharma

6 days ago - By: Biogen Inc. - Mentions: STOK

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

6 days ago - By: Stoke Therapeutics, Inc. - Mentions: STOK

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

6 days ago - By: Biogen Inc.

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

7 days ago - By: Eisai Inc.

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

7 days ago - By: Biogen Inc.

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

8 days ago - By: Zacks Investment Research - Mentions: MYGN

Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

8 days ago - By: Biogen Inc.

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

8 days ago - By: Eisai Inc.

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

10 days ago - By: Stoke Therapeutics, Inc. - Mentions: STOK

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

10 days ago - By: Biogen Inc.

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

13 days ago - By: Biogen Inc.

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

16 days ago - By: Biogen Inc.; Eisai Co., Ltd.

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

16 days ago - By: Eisai Inc.

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

17 days ago - By: Biogen Inc.

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

17 days ago - By: Biogen Inc.

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

17 days ago - By: Bloomberg

Biogen Reaches Research Deal With Dayra in Immunology Push

21 days ago - By: Biogen Inc.

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

21 days ago - By: Biogen Inc.

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

23 days ago - By: Zacks Investment Research - Mentions: JNJ ABBV

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3

24 days ago - By: Biogen Inc. - Mentions: STOK

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

24 days ago - By: Biogen Inc.

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

24 days ago - By: Biogen Inc. - Mentions: IONS

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

24 days ago - By: Biogen Inc.

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

a month ago - By: Biogen Inc. - Mentions: IONS

Biogen Completes Acquisition of Alcyone Therapeutics

a month ago - By: Biogen Inc.

Biogen Completes Acquisition of Alcyone Therapeutics

a month ago - By: Biogen Inc.

BIOGEN INC (BIIB) Stock News

BIIB Latest News, Press Relases and Analysis

What's going on in today's session: S&P500 gap up and gap down stocks

Which S&P500 stocks are moving before the opening bell on Monday?

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

Is Alnylam Pharmaceuticals a Millionaire Maker?

Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?

Denali Enters Into a $275M Funding Deal With Royalty Pharma

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Biogen Reaches Research Deal With Dayra in Immunology Push

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Biogen Completes Acquisition of Alcyone Therapeutics

Biogen Completes Acquisition of Alcyone Therapeutics

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom